{"id":"delavirdine","rwe":[{"pmid":"41406631","year":"2026","title":"Deciphering virus host interaction analysis to unravel core virus network signatures and computational drug repurposing for cervical cancer.","finding":"","journal":"Computers in biology and medicine","studyType":"Clinical Study"},{"pmid":"40120556","year":"2025","title":"Delavirdine modifies action potential configuration via inhibition of I(Kr) and I(to) in canine ventricular myocytes.","finding":"","journal":"Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","studyType":"Clinical Study"},{"pmid":"39509946","year":"2025","title":"Recent report on indoles as a privileged anti-viral scaffold in drug discovery.","finding":"","journal":"European journal of medicinal chemistry","studyType":"Clinical Study"},{"pmid":"39442074","year":"2024","title":"Design, Synthesis, Biological Evaluation and Molecular Docking Studies of New Thiazolidinone Derivatives as NNRTIs and SARS-CoV-2 Main Protease Inhibitors.","finding":"","journal":"Chemistry & biodiversity","studyType":"Clinical Study"},{"pmid":"30000604","year":"2006","title":"Delavirdine.","finding":"","journal":"","studyType":"Clinical Study"}],"tags":[{"label":"Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Histamine H4 receptor","category":"target"},{"label":"HRH4","category":"gene"},{"label":"ABCG2","category":"gene"},{"label":"MDH1","category":"gene"},{"label":"J05AG02","category":"atc"},{"label":"Off-Patent","category":"patent"},{"label":"Active","category":"status"},{"label":"Human immunodeficiency virus infection","category":"indication"},{"label":"Viiv Hlthcare","category":"company"},{"label":"Approved 1990s","category":"decade"},{"label":"Anti-HIV Agents","category":"pharmacology"},{"label":"Anti-Infective Agents","category":"pharmacology"},{"label":"Anti-Retroviral Agents","category":"pharmacology"},{"label":"Antiviral Agents","category":"pharmacology"},{"label":"Enzyme Inhibitors","category":"pharmacology"},{"label":"Nucleic Acid Synthesis Inhibitors","category":"pharmacology"},{"label":"Reverse Transcriptase Inhibitors","category":"pharmacology"}],"phase":"marketed","safety":{"safetySignals":[{"llr":615.092,"date":"","count":81,"signal":"Mitochondrial toxicity","source":"DrugCentral FAERS","actionTaken":"Reported 81 times (LLR=615)"},{"llr":583.981,"date":"","count":82,"signal":"Lipodystrophy acquired","source":"DrugCentral FAERS","actionTaken":"Reported 82 times (LLR=584)"},{"llr":577.568,"date":"","count":70,"signal":"Progressive external ophthalmoplegia","source":"DrugCentral FAERS","actionTaken":"Reported 70 times (LLR=578)"},{"llr":497.725,"date":"","count":81,"signal":"Eyelid ptosis","source":"DrugCentral FAERS","actionTaken":"Reported 81 times (LLR=498)"},{"llr":400.087,"date":"","count":81,"signal":"Diplopia","source":"DrugCentral FAERS","actionTaken":"Reported 81 times (LLR=400)"}],"drugInteractions":[{"url":"/drug/cyp2c19-substrates","drug":"CYP2C19 Substrates","action":"Use caution","effect":"Strong CYP2C19 Inhibitors - CYP2C19 Substrates","source":"DrugCentral","drugSlug":"cyp2c19-substrates"},{"url":"/drug/cyp2c9-substrates","drug":"CYP2C9 Substrates","action":"Use caution","effect":"Strong CYP2C9 Inhibitors - CYP2C9 Substrates","source":"DrugCentral","drugSlug":"cyp2c9-substrates"},{"url":"/drug/cyp2d6-substrates","drug":"CYP2D6 Substrates","action":"Use caution","effect":"Strong CYP2D6 Inducers - CYP2D6 Substrates","source":"DrugCentral","drugSlug":"cyp2d6-substrates"},{"url":"/drug/cyp3a4-substrates","drug":"CYP3A4 Substrates","action":"Use caution","effect":"Strong CYP3A4 Inhibitors - CYP3A4 Substrates","source":"DrugCentral","drugSlug":"cyp3a4-substrates"},{"url":"/drug/amprenavir","drug":"amprenavir","action":"Avoid combination","effect":"May interact with Amprenavir, Delavirdine Mesylate","source":"DrugCentral","drugSlug":"amprenavir"},{"url":"/drug/erythromycin","drug":"erythromycin","action":"Monitor closely","effect":"May interact with Delavirdine Mesylate, Erythromycin","source":"DrugCentral","drugSlug":"erythromycin"},{"url":"/drug/etravirine","drug":"etravirine","action":"Avoid combination","effect":"May interact with Delavirdine Mesylate, Etravirine","source":"DrugCentral","drugSlug":"etravirine"},{"url":"/drug/fosamprenavir","drug":"fosamprenavir","action":"Avoid combination","effect":"May interact with Delavirdine Mesylate, Fosamprenavir","source":"DrugCentral","drugSlug":"fosamprenavir"},{"url":"/drug/ixabepilone","drug":"ixabepilone","action":"Monitor closely","effect":"May interact with Delavirdine Mesylate, Ixabepilone","source":"DrugCentral","drugSlug":"ixabepilone"},{"url":"/drug/lovastatin","drug":"lovastatin","action":"Avoid combination","effect":"May interact with Delavirdine Mesylate, Lovastatin","source":"DrugCentral","drugSlug":"lovastatin"},{"url":"/drug/maraviroc","drug":"maraviroc","action":"Monitor closely","effect":"May interact with Delavirdine Mesylate, Maraviroc","source":"DrugCentral","drugSlug":"maraviroc"},{"url":"/drug/methylergometrine","drug":"methylergometrine","action":"Avoid combination","effect":"May interact with Delavirdine Mesylate, Methylergonovine","source":"DrugCentral","drugSlug":"methylergometrine"},{"url":"/drug/midazolam","drug":"midazolam","action":"Avoid combination","effect":"May interact with Delavirdine Mesylate, Midazolam","source":"DrugCentral","drugSlug":"midazolam"},{"url":"/drug/nelfinavir","drug":"nelfinavir","action":"Monitor closely","effect":"May interact with Delavirdine Mesylate, Nelfinavir Mesylate","source":"DrugCentral","drugSlug":"nelfinavir"},{"url":"/drug/phenobarbital","drug":"phenobarbital","action":"Avoid combination","effect":"May interact with Delavirdine Mesylate, Phenobarbital","source":"DrugCentral","drugSlug":"phenobarbital"},{"url":"/drug/phenytoin","drug":"phenytoin","action":"Avoid combination","effect":"May interact with Delavirdine Mesylate, Phenytoin","source":"DrugCentral","drugSlug":"phenytoin"},{"url":"/drug/quinidine","drug":"quinidine","action":"Monitor closely","effect":"May interact with Delavirdine Mesylate, Quinidine","source":"DrugCentral","drugSlug":"quinidine"},{"url":"/drug/ranolazine","drug":"ranolazine","action":"Avoid combination","effect":"May interact with Delavirdine Mesylate, Ranolazine","source":"DrugCentral","drugSlug":"ranolazine"},{"url":"/drug/rifabutin","drug":"rifabutin","action":"Avoid combination","effect":"May interact with Delavirdine Mesylate, Rifabutin","source":"DrugCentral","drugSlug":"rifabutin"},{"url":"/drug/rifampicin","drug":"rifampicin","action":"Avoid combination","effect":"May interact with Delavirdine Mesylate, Rifampin","source":"DrugCentral","drugSlug":"rifampicin"}],"commonSideEffects":[],"contraindications":["Achlorhydria","Breastfeeding (mother)","Disease of liver"]},"trials":[],"aliases":[],"company":"GSK","patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=DELAVIRDINE","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T00:31:24.687278+00:00"},"aiSummary":{"url":"","method":"ai_extraction","source":"AI Strategic Summary","aiModel":"featherless","rawText":"","confidence":0.9,"sourceType":"ai_extraction","retrievedAt":"2026-04-20T00:31:41.187314+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T00:31:30.243119+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=DELAVIRDINE","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T00:31:30.850713+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL593/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T00:31:31.554786+00:00"}},"allNames":"rescriptor","offLabel":[],"synonyms":["delavirdine","delavirdine mesylate","delavirdine mesilate","rescriptor"],"timeline":[{"date":"1997-01-01","type":"neutral","source":"FDA Orange Book","milestone":"Rights transferred from VIIV HLTHCARE to Viiv Hlthcare"},{"date":"1997-04-04","type":"positive","source":"DrugCentral","milestone":"FDA approval (Viiv Hlthcare)"}],"aiSummary":"Delavirdine (Rescriptor), marketed by GSK, is a non-nucleoside reverse transcriptase inhibitor (NNRTI) used in the treatment of HIV infection, competing in a crowded market with several other NNRTIs. Its key strength lies in its mechanism of action, which effectively binds to the reverse transcriptase enzyme, thereby preventing HIV replication. The primary risk is the strong competition from off-patent drugs like nevirapine and efavirenz, as well as patent-protected alternatives such as rilpivirine and doravirine, which may limit its market share.","approvals":[{"date":"1997-04-04","orphan":false,"company":"VIIV HLTHCARE","regulator":"FDA"}],"brandName":"Rescriptor","ecosystem":[{"indication":"Human immunodeficiency virus infection","otherDrugs":[{"name":"abacavir","slug":"abacavir","company":"Viiv Hlthcare"},{"name":"amprenavir","slug":"amprenavir","company":"Glaxosmithkline"},{"name":"atazanavir","slug":"atazanavir","company":"Bristol Myers Squibb"},{"name":"bictegravir","slug":"bictegravir","company":"Gilead Sciences Inc"}],"globalPrevalence":null}],"mechanism":{"target":"Histamine H4 receptor","novelty":"Follow-on","targets":[{"gene":"HRH4","source":"DrugCentral","target":"Histamine H4 receptor","protein":"Histamine H4 receptor"},{"gene":"ABCG2","source":"DrugCentral","target":"ATP-binding cassette sub-family G member 2","protein":"ATP-binding cassette sub-family G member 2"},{"gene":"MDH1","source":"DrugCentral","target":"Malate dehydrogenase cytoplasmic ","protein":"Malate dehydrogenase, cytoplasmic"}],"moaClass":"Non-Nucleoside Reverse Transcriptase Inhibitors","modality":"Small Molecule","drugClass":"Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor","explanation":"","oneSentence":"","technicalDetail":"Delavirdine binds to the reverse transcriptase enzyme at the NNRTI binding site, inducing a conformational change that prevents the enzyme from performing its catalytic function, thereby inhibiting viral replication."},"commercial":{"launchDate":"1997","_launchSource":"DrugCentral (FDA 1997-04-04, VIIV HLTHCARE)"},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/799","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=DELAVIRDINE","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=DELAVIRDINE","fields":["publications"],"source":"PubMed/NCBI"},{"id":4,"url":"https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files","fields":["patents","exclusivity","genericManufacturers"],"source":"FDA Orange Book"}],"_enrichedAt":"2026-03-30T10:31:13.089278","_validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-20T00:31:41.187399+00:00","fieldsConflicting":2,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"nevirapine","drugSlug":"nevirapine","fdaApproval":"1996-06-21","patentExpiry":"Mar 12, 2029","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"efavirenz","drugSlug":"efavirenz","fdaApproval":"1998-09-17","genericCount":8,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"etravirine","drugSlug":"etravirine","fdaApproval":"2008-01-18","genericCount":3,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"rilpivirine","drugSlug":"rilpivirine","fdaApproval":"2011-05-20","patentExpiry":"Oct 23, 2037","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"doravirine","drugSlug":"doravirine","fdaApproval":"2018-08-30","patentExpiry":"Aug 30, 2032","patentStatus":"Patent protected","relationship":"same-class"}],"genericName":"delavirdine","indications":{"approved":[{"name":"Human immunodeficiency virus infection","source":"DrugCentral","snomedId":86406008,"regulator":"FDA"}],"offLabel":[],"pipeline":[]},"currentOwner":"Viiv Hlthcare","drugCategory":"active","labelChanges":[],"patentStatus":"Off-patent — no active Orange Book patents","relatedDrugs":[{"drugId":"nevirapine","brandName":"nevirapine","genericName":"nevirapine","approvalYear":"1996","relationship":"same-class"},{"drugId":"efavirenz","brandName":"efavirenz","genericName":"efavirenz","approvalYear":"1998","relationship":"same-class"},{"drugId":"etravirine","brandName":"etravirine","genericName":"etravirine","approvalYear":"2008","relationship":"same-class"},{"drugId":"rilpivirine","brandName":"rilpivirine","genericName":"rilpivirine","approvalYear":"2011","relationship":"same-class"},{"drugId":"doravirine","brandName":"doravirine","genericName":"doravirine","approvalYear":"2018","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT02016924","phase":"PHASE2,PHASE3","title":"Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIV","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gilead Sciences","startDate":"2014-01-16","conditions":["Acquired Immune Deficiency Syndrome (AIDS)","HIV Infections"],"enrollment":133,"completionDate":"2027-03"},{"nctId":"NCT05502341","phase":"PHASE2,PHASE3","title":"Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With a Complicated Regimen","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gilead Sciences","startDate":"2022-08-16","conditions":["HIV-1-infection"],"enrollment":689,"completionDate":"2028-07"},{"nctId":"NCT00000891","phase":"PHASE2","title":"Immunologic and Virologic Consequences of Long-Term Highly Active Antiretroviral Therapy (HAART) in Subjects With Moderately Advanced HIV-1 Disease: A Follow-Up Study to ACTG 315","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":["HIV Infections"],"enrollment":34,"completionDate":"2004-05"},{"nctId":"NCT00000810","phase":"PHASE1","title":"Randomized, Phase I/II, Dose-Ranging, Open-Label Trial of the Anti-HIV Activity of Delavirdine Mesylate (DLV; U-90,152S)","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":["HIV Infections"],"enrollment":120,"completionDate":"1996-01"},{"nctId":"NCT00000892","phase":"NA","title":"A Study of Several Anti-HIV Drug Combinations in HIV-Infected Patients Who Have Used Indinavir","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":["HIV Infections"],"enrollment":300,"completionDate":"1999-08"},{"nctId":"NCT00000803","phase":"PHASE2","title":"A Phase II Double-Blind Study of Delavirdine Mesylate ( U-90152 ) in Combination With Zidovudine ( AZT ) and/or Didanosine ( ddI ) Versus AZT and ddI Combination Therapy","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":["HIV Infections"],"enrollment":471,"completionDate":"1997-03"},{"nctId":"NCT03631732","phase":"PHASE3","title":"Study to Evaluate Switching From a Regimen of Two Nucleos(t)Ide Reverse Transcriptase Inhibitors (NRTI) Plus a Third Agent to a Fixed Dose Combination (FDC) of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF), in Virologically-Suppressed, HIV-1 Infected African American Participants","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2018-08-28","conditions":["HIV-1 Infection"],"enrollment":496,"completionDate":"2020-08-19"},{"nctId":"NCT00925756","phase":"PHASE4","title":"CCR5 Inhibitor Treatment Intensification on CD4+ T-cell Recovery","status":"COMPLETED","sponsor":"University of California, San Diego","startDate":"2008-10-20","conditions":["HIV Infections"],"enrollment":32,"completionDate":"2014-04-11"},{"nctId":"NCT01814722","phase":"","title":"Quality of Life of HIV-infected Participants Switched to Raltegravir Versus Other Antiretroviral Regimens (MK-0518-266)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2012-11-09","conditions":["Human Immunodeficiency Virus"],"enrollment":63,"completionDate":"2013-10-31"},{"nctId":"NCT00445146","phase":"PHASE2","title":"Safety of EVG+RTV Administered With Other Antiretroviral Agents for the Treatment of HIV-1 Infection","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2007-02","conditions":["HIV Infections"],"enrollment":192,"completionDate":"2015-03"},{"nctId":"NCT00001094","phase":"PHASE2","title":"A Comparison of Nelfinavir Plus Saquinavir Plus Delavirdine or 3TC/ZDV Versus Nelfinavir Plus 3TC/ZDV in HIV-Infected Patients","status":"WITHDRAWN","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":["HIV Infections"],"enrollment":0,"completionDate":""},{"nctId":"NCT02249130","phase":"PHASE2","title":"Tipranavir Dose-response Study Using a Prototype Self-emulsifying Drug Delivery System (SEDDS) Formulation in Treatment-naive HIV-1 Infected Patients Report on the Post-study Option, a Treatment of Triple Therapy With Delavirdine, ZDV and 3TC Without Tipranavir","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"1999-03","conditions":["HIV Infections"],"enrollment":18,"completionDate":""},{"nctId":"NCT00624195","phase":"PHASE2,PHASE3","title":"Clinical Trial of CNS-targeted HAART (CIT2)","status":"COMPLETED","sponsor":"University of California, San Diego","startDate":"2007-03","conditions":["HIV Infections"],"enrollment":59,"completionDate":"2012-06"},{"nctId":"NCT00000882","phase":"PHASE2","title":"Virologic and Immunologic Activity of Continued Lamivudine (3TC) vs Delavirdine (DLV) in Combination With Indinavir (IDV) and Zidovudine (ZDV) or Stavudine (d4T) in 3TC-Experienced Subjects","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":["HIV Infections"],"enrollment":300,"completionDate":""},{"nctId":"NCT00823966","phase":"","title":"Safety And Efficacy Of Rescriptor In Patients For Human Immunodeficiency Virus (HIV) Patients","status":"COMPLETED","sponsor":"Pfizer","startDate":"2003-12","conditions":["HIV-1 Infection"],"enrollment":3,"completionDate":"2009-03"},{"nctId":"NCT00002420","phase":"PHASE2","title":"The Safety and Effectiveness of Didanosine Plus Stavudine Plus Delavirdine Mesylate Plus MKC-442 in HIV-Infected Patients Who Have Not Had Success With Protease Inhibitors","status":"TERMINATED","sponsor":"Bristol-Myers Squibb","startDate":"","conditions":["HIV Infections"],"enrollment":25,"completionDate":""},{"nctId":"NCT00002378","phase":"PHASE3","title":"A Comparison of Three Anti-HIV Drug Combinations Containing Saquinavir Soft Gelatin Capsules Used in HIV-1 Infected Patients","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"","conditions":["HIV Infections"],"enrollment":825,"completionDate":""},{"nctId":"NCT00002123","phase":"PHASE3","title":"A Double-Blind, Randomized, Comparative Study of Delavirdine Mesylate (U-90152S) in Combination With Didanosine (ddI) Versus ddI Alone in HIV-1 Infected Individuals With CD4 Counts of <= 300/mm3","status":"COMPLETED","sponsor":"Pharmacia and Upjohn","startDate":"","conditions":["HIV Infections"],"enrollment":0,"completionDate":""},{"nctId":"NCT00002400","phase":"NA","title":"A Study of Two Anti-HIV Drug Combinations in HIV-Infected Patients","status":"COMPLETED","sponsor":"Pharmacia and Upjohn","startDate":"","conditions":["HIV Infections"],"enrollment":45,"completionDate":""},{"nctId":"NCT00002211","phase":"NA","title":"Safety and Effectiveness of Giving Combinations of Three or Four Anti-HIV Drugs to HIV-Infected Patients","status":"COMPLETED","sponsor":"Pharmacia and Upjohn","startDate":"","conditions":["HIV Infections"],"enrollment":160,"completionDate":""},{"nctId":"NCT00002236","phase":"NA","title":"A Study to Find the Best Dosing Schedule for Delavirdine, Zidovudine, and Indinavir in HIV-Positive Patients","status":"COMPLETED","sponsor":"Pharmacia and Upjohn","startDate":"","conditions":["HIV Infections"],"enrollment":32,"completionDate":""},{"nctId":"NCT00002178","phase":"PHASE3","title":"A Phase IIIB Open-Label, Comparative Study to Evaluate Saquinavir Soft Gel Capsule (SGC) Treatment in Combination With Other Antiretrovirals in HIV-1 Infected Antiretroviral-Naive Patients","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"","conditions":["HIV Infections"],"enrollment":375,"completionDate":""},{"nctId":"NCT00002210","phase":"PHASE2","title":"A Study of Delavirdine Mesylate in Combination With Other Anti-HIV Drugs in HIV-Infected Children and Babies","status":"COMPLETED","sponsor":"Pharmacia and Upjohn","startDate":"","conditions":["HIV Infections"],"enrollment":24,"completionDate":""},{"nctId":"NCT00002312","phase":"NA","title":"The Safety and Effectiveness of U-90152 in HIV-1 Infected Patients Who Take Zidovudine","status":"COMPLETED","sponsor":"Pharmacia and Upjohn","startDate":"","conditions":["HIV Infections"],"enrollment":0,"completionDate":""},{"nctId":"NCT00002401","phase":"NA","title":"A Study of Delavirdine Used Together With Other Anti-HIV Drugs in HIV-Infected Patients","status":"COMPLETED","sponsor":"Pharmacia and Upjohn","startDate":"","conditions":["HIV Infections"],"enrollment":160,"completionDate":""},{"nctId":"NCT00006326","phase":"NA","title":"Safety and Effectiveness of 3 Anti-HIV Treatments in Patients Who Have Failed Previous Treatments Containing Nelfinavir","status":"TERMINATED","sponsor":"Agouron Pharmaceuticals","startDate":"2000-08","conditions":["HIV Infections"],"enrollment":60,"completionDate":""},{"nctId":"NCT00002124","phase":"PHASE3","title":"A Double-Blind, Randomized, Dose Response Study of Three Doses of Delavirdine Mesylate (U-90152S) in Combination With Zidovudine (ZDV) Versus ZDV Alone in HIV-1 Infected Individuals With CD4 Counts of 200-500mm3","status":"COMPLETED","sponsor":"Pharmacia and Upjohn","startDate":"","conditions":["HIV Infections"],"enrollment":1250,"completionDate":""}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"_patentsChecked":true,"crossReferences":{"NUI":"N0000022056","MMSL":"4541","NDDF":"006463","UNII":"DOL5F9JD3E","VUID":"4024051","CHEBI":"CHEBI:119573","VANDF":"4021011","INN_ID":"7234","RXNORM":"142152","UMLSCUI":"C0288165","chemblId":"CHEMBL593","ChEMBL_ID":"CHEMBL593","KEGG_DRUG":"D00895","DRUGBANK_ID":"DB00705","PDB_CHEM_ID":" SPP","PUBCHEM_CID":"5625","SNOMEDCT_US":"108710001","IUPHAR_LIGAND_ID":"12674","SECONDARY_CAS_RN":"147221-93-0","MESH_DESCRIPTOR_UI":"D020008"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[{"period":"1997-","companyName":"Viiv Hlthcare","relationship":"Original Developer"}],"pharmacokinetics":{"source":"DrugCentral","bioavailability":"85%"},"publicationCount":362,"therapeuticAreas":["Immunology"],"atcClassification":{"source":"DrugCentral","atcCode":"J05AG02","allCodes":["J05AG02"]},"biosimilarFilings":[],"originalDeveloper":"Viiv Hlthcare","recentPublications":[{"date":"2026 Jan 1","pmid":"41406631","title":"Deciphering virus host interaction analysis to unravel core virus network signatures and computational drug repurposing for cervical cancer.","journal":"Computers in biology and medicine"},{"date":"2025 May","pmid":"40120556","title":"Delavirdine modifies action potential configuration via inhibition of I(Kr) and I(to) in canine ventricular myocytes.","journal":"Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie"},{"date":"2025 Jan 5","pmid":"39509946","title":"Recent report on indoles as a privileged anti-viral scaffold in drug discovery.","journal":"European journal of medicinal chemistry"},{"date":"2024 Dec","pmid":"39442074","title":"Design, Synthesis, Biological Evaluation and Molecular Docking Studies of New Thiazolidinone Derivatives as NNRTIs and SARS-CoV-2 Main Protease Inhibitors.","journal":"Chemistry & biodiversity"},{"date":"2006","pmid":"30000604","title":"Delavirdine.","journal":""}],"companionDiagnostics":[],"genericManufacturers":0,"_genericFilersChecked":true,"genericManufacturerList":[],"status":"approved","companyName":"Viiv Hlthcare","companyId":"gsk","modality":"Small molecule","firstApprovalDate":"1997","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":"1997-04-04T00:00:00.000Z","mah":"VIIV HLTHCARE","brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":"1997-04-04T00:00:00.000Z","mah":"VIIV HLTHCARE","brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":"1997-04-04T00:00:00.000Z","mah":"VIIV HLTHCARE","brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":"1997-04-04T00:00:00.000Z","mah":"VIIV HLTHCARE","brand_name_local":null,"application_number":null},{"country_code":"SA","regulator":"SFDA","status":"likely_approved","approval_date":"1997-04-04T00:00:00.000Z","mah":"VIIV HLTHCARE","brand_name_local":null,"application_number":null},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"1997-04-04T00:00:00.000Z","mah":"VIIV HLTHCARE","brand_name_local":null,"application_number":""},{"country_code":"IN","regulator":"CDSCO","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TH","regulator":"FDA-TH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"MY","regulator":"NPRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"PH","regulator":"FDA-PH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"CO","regulator":"INVIMA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"ZA","regulator":"SAHPRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TW","regulator":"TFDA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"HK","regulator":"DH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"BR","regulator":"ANVISA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"MX","regulator":"COFEPRIS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AR","regulator":"ANMAT","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TR","regulator":"TITCK","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-20T00:31:41.187399+00:00","fieldsConflicting":2,"overallConfidence":0.8},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}